In the published article, there was an error in the description of the regulatory status of TJ0113. The article incorrectly stated that TJ0113 had received clinical approval for Alport syndrome from both the China National Medical Products Administration and the U.S. Food and Drug Administration. In fact, TJ0113 has only been approved to initiate a Phase I clinical trial in China (CTR20232426) for the treatment of Alport syndrome, and has not received clinical approval for this indication from the U.S. Food and Drug Administration.
A correction has been made to Abstract, Paragraph 1. This sentence previously stated:
“TJ0113 has received clinical approval for Alport syndrome from both the China National Medical Products Administration and the U.S. Food and Drug Administration.”
The corrected sentence appears below:
“TJ0113 has been approved to initiate a Phase I clinical trial for Alport syndrome and a Phase II trial for Parkinson’s disease in China.”
A correction has been made to Discussion, Paragraph 2. This sentence previously stated:
“Notably, TJ0113 has received clinical approval for the treatment of Alport syndrome from both the China National Medical Products Administration and the U.S. Food and Drug Administration, and is currently undergoing further clinical evaluation for Parkinson’s disease and depression (ClinicalTrials.gov ID: NCT06832540, NCT06596005; CTR20232426).”
The corrected sentence appears below:
“Notably, TJ0113 has been approved to initiate clinical trial for Alport syndrome, Parkinson’s disease and depression in China (CTR20232426, CTR20243324, CTR20252210).”
The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
acute lung injury, mitophagy inducer, TJ0113, NF-κB, NLRP3 inflammasome
Citation
Liu Z, Fang D, Chen K, Dong L, Huang H and Chen Z (2025) Correction: Novel mitophagy inducer TJ0113 alleviates pulmonary inflammation during acute lung injury. Front. Pharmacol. 16:1667879. doi: 10.3389/fphar.2025.1667879
Received
17 July 2025
Accepted
25 July 2025
Published
07 August 2025
Volume
16 - 2025
Edited and reviewed by
Chun Xu, The University of Sydney, Australia
Updates
Copyright
© 2025 Liu, Fang, Chen, Dong, Huang and Chen.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zhihua Chen, zhihuachen@zju.edu.cn; Huaqiong Huang, zr_hhq@zju.edu.cn
†These authors have contributed equally to this work and share first authorship
‡These authors have contributed equally to this work and share last authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.